Physician profile
Maureen Zelinka
NPI 1336119718
$2,399.17
in general payments reported to CMS, 2019-2025
27 companies · $210 in 2025
The $210 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $504 · 2020: $445 · 2021: $416 · 2022: $323 · 2023: $264 · 2024: $235 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $710.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $319.62 | 2019 | |
| Pfizer INC. | $295.17 | 2019-2025 | |
| Lilly USA, LLC | $245.18 | 2020-2025 | Jardiance |
| Abbvie INC. | $218.96 | 2021-2025 | Ubrelvy, Vraylar |
| Glaxosmithkline, LLC. | $121.92 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Abbott Laboratories | $112.15 | 2021-2025 | Freestyle Libre 3 |
| Mylan Specialty L.P. | $110.94 | 2020-2023 | Yupelri |
| Novo Nordisk INC | $109.08 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $108.93 | 2021-2023 | |
| Sunovion Pharmaceuticals INC. | $76.25 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $75.39 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $72.48 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $69.12 | 2022-2025 | Airsupra, Breztri |
| Amarin Pharma, INC. | $54.79 | 2020 | |
| Lundbeck LLC | $48.87 | 2024 | Rexulti |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $47.65 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $44.85 | 2022 | |
| Amgen INC. | $39.76 | 2023-2025 | Repatha, Otezla, Repatha |
| Teva Pharmaceuticals USA, INC. | $35.72 | 2021-2025 | Austedo Xr |
| Eisai INC. | $29.23 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $28.63 | 2023 | Rexulti |
| Boston Scientific Corporation | $26.95 | 2023 | Watchman Access System |
| Exact Sciences Corporation | $26.57 | 2024 | Cologuard Collection Kit |
| Corcept Therapeutics | $25.52 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.23 | 2024 | |
| Almatica Pharma LLC | $21.05 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maureen Zelinka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.